Hirokazu Taniguchi1, Kumpei Tanisawa1, Xiaomin Sun1, Takafumi Kubo1, Mitsuru Higuchi1. 1. Graduate School of Sport Sciences (H.T., X.S., T.K.), Waseda University, Tokorozawa 359-1192, Japan; Faculty of Sport Sciences (K.T., M.H.), Waseda University, Tokorozawa 359-1192, Japan; Japan Society for the Promotion of Science (K.T.), Tokyo 102-8472, Japan; Institute of Advanced Active Aging Research (M.H.), Tokorozawa 359-1192, Japan.
Abstract
CONTEXT: Age-related hepatic fat accumulation increases the risk of cardiometabolic diseases, and the fibroblast growth factor (FGF) 21-resistant state caused by fatty liver underlies the pathogenesis of these diseases. OBJECTIVE: Previous studies suggested that a higher level of cardiorespiratory fitness was associated with both lower hepatic fat content and serum FGF21 levels; however, the effect of endurance exercise on hepatic fat content and serum FGF21 concentration has not been studied. Therefore, we aimed to elucidate whether endurance exercise reduced hepatic fat content and serum FGF21 levels. DESIGN: This is a randomized crossover trial. SETTING: The study setting was an institutional practice. PATIENTS: Thirty-three elderly Japanese men participated in the study. INTERVENTION: The intervention was a 5-week endurance exercise program comprising three cycle ergometer sessions per week. MAIN OUTCOME MEASURES: Hepatic fat content was assessed by proton magnetic resonance spectroscopy, and serum FGF21 level was determined by ELISA. RESULTS: A 5-week endurance exercise program decreased the hepatic fat content and serum FGF21 levels without weight loss, and the changes were higher in the exercise period than in the control period (P = .021 and P = .026, respectively). Correlation analysis demonstrated that only the change in hepatic fat content was significantly and positively correlated with change in serum FGF21 levels (r = 0.366, P = .006). CONCLUSIONS: A 5-week endurance exercise program decreased hepatic fat content and serum FGF21 levels without weight loss in elderly men, and exercise-induced hepatic fat reduction mediated the reduction in serum FGF21 levels. These findings suggest that endurance exercise modulates hepatic fat content and FGF21 resistance, regardless of obesity status.
RCT Entities:
CONTEXT: Age-related hepatic fat accumulation increases the risk of cardiometabolic diseases, and the fibroblast growth factor (FGF) 21-resistant state caused by fatty liver underlies the pathogenesis of these diseases. OBJECTIVE: Previous studies suggested that a higher level of cardiorespiratory fitness was associated with both lower hepatic fat content and serum FGF21 levels; however, the effect of endurance exercise on hepatic fat content and serum FGF21 concentration has not been studied. Therefore, we aimed to elucidate whether endurance exercise reduced hepatic fat content and serum FGF21 levels. DESIGN: This is a randomized crossover trial. SETTING: The study setting was an institutional practice. PATIENTS: Thirty-three elderly Japanese men participated in the study. INTERVENTION: The intervention was a 5-week endurance exercise program comprising three cycle ergometer sessions per week. MAIN OUTCOME MEASURES: Hepatic fat content was assessed by proton magnetic resonance spectroscopy, and serum FGF21 level was determined by ELISA. RESULTS: A 5-week endurance exercise program decreased the hepatic fat content and serum FGF21 levels without weight loss, and the changes were higher in the exercise period than in the control period (P = .021 and P = .026, respectively). Correlation analysis demonstrated that only the change in hepatic fat content was significantly and positively correlated with change in serum FGF21 levels (r = 0.366, P = .006). CONCLUSIONS: A 5-week endurance exercise program decreased hepatic fat content and serum FGF21 levels without weight loss in elderly men, and exercise-induced hepatic fat reduction mediated the reduction in serum FGF21 levels. These findings suggest that endurance exercise modulates hepatic fat content and FGF21 resistance, regardless of obesity status.
Authors: Justin A Fletcher; Melissa A Linden; Ryan D Sheldon; Grace M Meers; E Matthew Morris; Anthony Butterfield; James W Perfield; John P Thyfault; R Scott Rector Journal: Am J Physiol Gastrointest Liver Physiol Date: 2016-03-24 Impact factor: 4.052
Authors: Laurie R Braun; Meghan N Feldpausch; Natalia Czerwonka; Martin Torriani; Steven K Grinspoon; Takara L Stanley Journal: Growth Horm IGF Res Date: 2017-10-07 Impact factor: 2.372
Authors: Nicole G Barra; Isabella Y Fan; Jenna B Gillen; Marianne Chew; Katarina Marcinko; Gregory R Steinberg; Martin J Gibala; Ali A Ashkar Journal: J Cancer Prev Date: 2017-12-30
Authors: Nicola Morrice; George D Mcilroy; Seshu R Tammireddy; Jennifer Reekie; Kirsty D Shearer; Mary K Doherty; Mirela Delibegović; Phillip D Whitfield; Nimesh Mody Journal: Sci Rep Date: 2017-03-03 Impact factor: 4.379